<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119275">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01817270</url>
  </required_header>
  <id_info>
    <org_study_id>NCT02038506</org_study_id>
    <nct_id>NCT01817270</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine</brief_title>
  <official_title>A Study to Evaluate the Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changchun Keygen Biological Products Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangdong Provincial Institute of Biological Products And Materia Medica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Changchun Keygen Biological Products Co., Ltd.</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe the occurrence of adverse events, seroconversion
      rate and geometric mean titres(GMTs) of 2 doses of live attenuated varicella vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Seroconversion rate and GMTs for live attenuated varicella vaccine</measure>
    <time_frame>35-42 days after the first and second doses</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>within 30 days after each vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">368</enrollment>
  <condition>Chickenpox</condition>
  <arm_group>
    <arm_group_label>Live Attenuated Varicella Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use the left arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live Attenuated Varicella Vaccine</intervention_name>
    <arm_group_label>Live Attenuated Varicella Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parent/legal acceptable representative is willing and able to understand the protocol
             requirements and provide informed consent

          -  Participant is aged ≥ 1 year to ≤ 3 years

          -  Participant without preventive inoculation of varicella vaccine and previous history
             of chickenpox and zoster

          -  Subject and parent/guardian able to attend all scheduled visits and comply with all
             trial procedures

          -  Body temperature ≤ 37.5℃

        Exclusion Criteria:

          -  Known allergy to any constituent of the vaccine

          -  Known acute illness, severe chronic disease, acute exacerbation of chronic disease
             and fever

          -  Known or suspected impairment of immunologic function, or receipt of
             immunosuppressive therapy or immunoglobulin since birth

          -  Reported the history of allergies, convulsions, epilepsy, mental illness and brain
             disease and clear serious systemic reaction

          -  Failed to the Expanded Programme on Immunization(EPI)

          -  Receipt of any vaccine in the 4 weeks preceding the trial vaccination

          -  Plan to receive any vaccine in the 4 weeks following the trial vaccination

          -  Known bleeding disorder

          -  Receipt of whole blood, blood plasma or immunoglobulin in the 5 months preceding the
             trial vaccination

          -  Reported the history of acute illness had need systemic antibiotics or anti-viral
             treatment of infections in the 7 days preceding the trial vaccination

          -  An acute illness with or without fever (temperature ≥ 38.0℃) in the 3 days preceding
             enrollment in the trial

          -  Participation in any other interventional clinical trial

          -  Any condition which, in the opinion of the investigator, would pose a health risk to
             the subject or interfere with the vaccine
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huizhen Zheng, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xinxing Center for Disease Control and Prevention</name>
      <address>
        <city>Yunfu</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 14, 2013</lastchanged_date>
  <firstreceived_date>March 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chickenpox</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
